Friday, 19 Jul 2019

You are here

EULAR 2019 Update to Lupus Management

The EULAR recommendations for the management of systemic lupus erythematosus (SLE) have been updated based on emerging new evidence and after a systematic literature review, Delphi process and expert opinions to reach consensus. The following is exerpted from the Annals of Rheumatic Diseases article.

Overarching Principles

  • SLE is a multisystem disease—occasionally limited to one or few organs—diagnosed on clinical grounds in the presence of characteristic serological abnormalities.
  • SLE care is multidisciplinary, based on a shared patient-physician decision, and should consider individual, medical and societal costs.
  • Treatment of organ-threatening/life-threatening SLE includes an initial period of high-intensity immunosuppressive therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate response and prevent relapses.
  • Treatment goals include long-term patient survival, prevention of organ damage and optimisation of health-related quality of life.


Goals of treatment

  • Treatment in SLE should aim at remission or low disease activity and prevention of flares in all organs, maintained with the lowest possible dose of glucocorticoids. 
  • Flares of SLE can be treated according to the severity of organ(s) involvement by adjusting ongoing therapies (glucocorticoids, immunomodulating agents) to higher doses, switching or adding new therapies 

Hydroxychloroquine (HCQ)

  • HCQ is recommended for all patients with SLE, unless contraindicated, at a dose not exceeding 5 mg/kg/real BW 
  • In the absence of risk factors for retinal toxicity, ophthalmological screening (by visual fields examination and/or spectral domain-optical coherence tomography) should be performed at baseline, after 5 years, and yearly thereafter

Glucocorticoids (GC)

  • GC can be used at doses and route of administration that depend on the type and severity of organ involvement 
  • Pulses of intravenous methylprednisolone (usually 250–1000 mg per day, for 1–3 days) provide immediate therapeutic effect and enable the use of lower starting dose of oral GC
  • For chronic maintenance treatment, GC should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. 
  • Prompt initiation of immunomodulatory agents can expedite the tapering/discontinuation of GC

Immunosuppressive therapies

  • In patients not responding to HCQ (alone or in combination with GC) or patients unable to reduce GC below doses acceptable for chronic use, addition of immunomodulating/immunosuppressive agents such as methotrexate, azathioprine or mycophenolate should be considered.
  • Immunomodulating/immunosuppressive agents can be included in the initial therapy in cases of organ-threatening disease
  • Cyclophosphamide can be used for severe organ-threatening or life-threatening SLE as well as ‘rescue’ therapy in patients not responding to other immunosuppressive agents


  • In patients with inadequate response to standard-of-care (combinations of HCQ and GC with or without immunosuppressive agents), defined as residual disease activity not allowing tapering of glucocorticoids and/or frequent relapses, add-on treatment with belimumab should be considered
  • In organ-threatening disease refractory or with intolerance/contraindications to standard immunosuppressive agents, rituximab can be considered

Skin disease

  • First-line treatment of skin disease in SLE includes topical agents (GC, calcineurin inhibitors), antimalarials (HCQ, quinacrine) and/or systemic GC
  • In non-responsive cases or cases requiring high-dose GC, methotrexate, retinoids,dapsone or mycophenolate can be added.

Neuropsychiatric disease

  • Attribution to SLE—as opposed to non-SLE—related neuropsychiatric manifestations, is essential and can be facilitated by neuroimaging, investigation of cerebrospinal fluid, consideration of risk factors (type and timing of the manifestation in relation to the onset of lupus, patient age, non-neurological lupus activity, presence of aPL) and exclusion of confounding factors 
  • Treatment of SLE-related neuropsychiatric disease includes glucocorticoids/immunosuppressive agents for manifestations considered to reflect an inflammatory process, and antiplatelet/anticoagulants for atherothrombotic/aPL-related manifestations

Haematological disease

  • Acute treatment of lupus thrombocytopenia includes high-dose GC (including pulses of intravenous methylprednisolone) and/or intravenous immunoglobulin G
  • For maintenance of response, immunosuppressive/GC-sparing agents such as mycophenolate, azathioprine or cyclosporine can be used.
  • Refractory cases can be treated with rituximab or cyclophosphamide

Renal disease

  • Early recognition of signs of renal involvement and—when present—performance of a diagnostic renal biopsy are essential to ensure optimal outcomes
  • Mycophenolate or low-dose intravenouscyclophosphamide are recommended as initial (induction) treatment, as they have the best efficacy/toxicity ratio.
  • In patients at high risk for renal failure (reduced glomerular filtration rate, histological presence of fibrous crescents or fibrinoid necrosis, or tubular atrophy/interstitial fibrosis], similar regimens may be considered but high-dose intravenous cyclophosphamide can also be used
  • For maintenance therapy, mycophenolate or azathioprine should be used.
  • In cases with stable/improved renal function but incomplete renal response (persistent proteinuria >0.8–1 g/24 hours after at least 1 year of immunosuppressive treatment), repeat biopsy can distinguish chronic from active kidney lesions
  • Mycophenolate may be combined with low dose of a calcineurin inhibitor in severe nephrotic syndrome or incomplete renal response, in the absence of uncontrolled hypertension, high chronicity index at kidney biopsy and/or reduced GFR.
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cardiovascular Disease Increased in Hospitalized Lupus Patients

Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. 

Pregnancy Outcomes Improve in Lupus

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve. The large decline in in-hospital maternal mortality was greater for lupus pregnancies than for non-lupus pregnancies. Findings from a retrospective cohort study are published in Annals of Internal Medicine.

Blinded by the Use of Antimalarials in Lupus?

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Disparities in Lupus Survival

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively). Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.